Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics
Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics
03/12/25, 6:48 AM
Location
edmontonMoney
$199 million
Industry
therapeutics
biotechnology
health care
Type
partnership
Entos Pharmaceuticals has announced a $198.5 million partnership with the Governments of Canada and Alberta to accelerate the biomanufacturing of Fusogenix PLV next generation therapeutics. The investment will help build an R&D center and a GMP manufacturing facility in Edmonton, Alberta, aiming to foster collaborations between Entos, Canadian academic institutions, and its industry partners.
Company Info
Location
edmonton, england, united kingdom
Additional Info
Entos Pharmaceuticals is a clinical-stage genetic medicines company focused on developing cures and improving patients' lives using its proprietary Fusogenix™ PLV™ technology. The company aims to address rare genetic disorders through innovative genetic medicine approaches. Since its founding in 2016, Entos has been committed to advancing next-generation genetic medicines.